Market Too Focused on Corteva's Near Term
We see long-term potential for this wide-moat seed and chemical producer.
Since seed and crop chemical company Corteva (CTVA) was spun out of DowDuPont in June, we think the market has focused on near-term uncertainties like the effects of flooded U.S. fields and the dry start to the Brazilian planting season. However, we continue to expect a full rebound in U.S. agricultural input demand in 2020. Because the planting season has just begun in Brazil, we think it is too early to determine any impact on crop plantings this season. If plantings pick up in October, the effect could be that sales simply shift from Corteva’s third quarter to the fourth, similar to the delayed U.S. plantings in 2018. Regardless, we remain optimistic on Corteva’s long-term outlook and view the shares as undervalued.
Corteva is a leader in the development of new seeds and crop chemicals. Its product portfolio skews toward seeds, which generated 56% of revenue in 2018. The company develops its pipeline by investing nearly 11% of sales in research and development, which outpaces all competitors. This should allow Corteva’s sales and profits to continue to grow even as patents expire and generic products come to market.
Seth Goldstein does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.
Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.
We’d like to share more about how we work and what drives our day-to-day business.
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.
How we use your information depends on the product and service that you use and your relationship with us. We may use it to:
To learn more about how we handle and protect your data, visit our privacy center.
Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.
To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.
Read our editorial policy to learn more about our process.